Obesity as an independent risk for left ventricular diastolic dysfunction in 692 Japanese patients

Kinuko Dote, Yoko Miyasaka1, Satoshi Tsujimoto

  • 1Cardiovascular Division, Department of Medicine II, Kansai Medical University, Hirakata, Osaka, Japan.

Insights

Obesity is independently linked to left ventricular (LV) diastolic dysfunction, a key indicator of heart disease risk. This finding highlights the importance of weight management for cardiovascular health.

Area of Science:

  • Cardiology
  • Obesity Research
  • Diagnostic Imaging

Background:

  • Obesity and left ventricular (LV) diastolic dysfunction are significant risk factors for cardiovascular morbidity and mortality.
  • Limited data exists on the independent association between obesity and LV diastolic dysfunction.

Purpose of the Study:

  • To investigate whether obesity is independently associated with LV diastolic dysfunction.
  • To assess the risk of abnormal LV diastolic function in relation to Body Mass Index (BMI) categories.

Main Methods:

  • Prospective study of 692 adult patients with sinus rhythm undergoing transthoracic echocardiography.
  • Exclusion of patients with pre-existing heart conditions or impaired LV systolic function.
  • Classification of diastolic function using mitral/pulmonary venous flow and Doppler tissue imaging; BMI categorized as normal, overweight, or obese.

Main Results:

  • 78% of patients exhibited abnormal LV diastolic function.
  • Obesity (BMI ≥30 kg/m²) was independently associated with LV diastolic dysfunction (OR: 2.98, P=0.03), even after adjusting for cardiovascular risk factors.
  • This association remained significant when accounting for LV mass (OR: 2.88, P=0.04); overweight status showed no independent association.

Conclusions:

  • Obesity is an independent risk factor for left ventricular diastolic dysfunction.
  • The association between obesity and diastolic dysfunction persists irrespective of other cardiovascular risk factors and LV mass.
Abstract

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
368
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.9K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
440
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
324